FDA Fast-Tracks Investigational Glioma Imaging Agent
The FDA has granted fast track designation to TLX101-CDx, an investigational product for imaging gliomas. The move signals momentum for molecular imaging agents that combine diagnostic and therapeutic capabilities. This is a growing area of interest for advanced specialty imaging centers.
The Fast Track designation is intended to speed up the development and review of drugs for serious conditions with unmet medical needs. This allows for more frequent meetings with the FDA and a rolling review process, where sections of the New Drug Application (NDA) can be submitted as they are completed. For imaging agents like TLX101-CDx, this signals a recognized need for better diagnostic tools in challenging diseases like glioma. TLX101-CDx (18F-floretyrosine) is a PET imaging agent that targets the LAT1 and LAT2 amino acid transport proteins, which are overexpressed in glioma cells. This allows it to potentially distinguish between tumor recurrence and changes due to treatment, a common challenge with conventional MRI. MRI, while a standard for anatomical imaging, can show enhancement from both tumor growth and post-radiation effects, leading to ambiguity. This agent is the companion diagnostic to the investigational therapy TLX101, which uses the same targeting mechanism to deliver therapeutic radiation directly to cancer cells. This "theranostic" approach—combining diagnostics and therapy—is a growing field in oncology, aiming to treat only the tumors that are seen on the scan. The success of this approach has been seen in other cancers, like prostate cancer with PSMA-targeted therapies. Amino acid PET imaging, using tracers like 18F-FET, has shown advantages over standard FDG-PET for brain tumors due to better tumor-to-background contrast. The IPAX-1 and IPAX-Linz clinical trials have investigated TLX101 in recurrent glioblastoma, with the IPAX-2 study exploring its use in newly diagnosed patients. Data from the IPAX-Linz trial showed a median overall survival of 12.4 months from the start of TLX101 treatment in patients with recurrent high-grade glioma. Despite the Fast Track designation, the FDA issued a Complete Response Letter (CRL) for the TLX101-CDx New Drug Application in May 2025, requesting additional clinical evidence. While no safety concerns were raised, this indicates a higher bar for approval and the need for more robust data to confirm the agent's efficacy and utility in clinical decision-making. Telix Pharmaceuticals plans to meet with the FDA to determine the path forward.
